Assoc. Prof. MD. Ozan Balakan

Education & Specialization

• Istanbul University, Istanbul Faculty of Medicine

• Dicle University, Internal Medicine Residency

• Gaziantep University, Medical Oncology Fellowship

Professional Experience

• Dicle University Faculty of Medicine, Department of Internal Medicine

• Gülhane Military Medical Academy, Department of Endocrinology

• Gaziantep University, Department of Medical Oncology

• KSU Faculty of Medicine, Department of Medical Oncology

Languages

• English

International Peer-Reviewed Journal Articles (SCI, SCCI, AHC1)

• Sayarlıoğlu M, Sayarlıoğlu H, Özkaya M, Balakan O, Uçar MA. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and adult onset Still's disease: case report and review of the literature. Mod Rheumatol. 2008;18(4):403–406.

• Pehlivan Y, Turkbeyler IH, Balakan O, Sevinc A, Yilmaz M, Bakir K, Onat AM. Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study. Rheumatol Int. 2011 Mar 30.

• Inal A, Kos FT, Algin E, Yildiz R, Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan MA, Durnali AG, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M, Isikdogan A. Gemcitabine alone versus combination of Gemcitabine and Cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). Neoplasma. 2012;59(3):297–301.

• Inal A, Kos FT, Algin E, Yildiz R, Berk V, Tugba Unek I, Colak D, Colak D, Kucukoner M, Tamer Elkiran E, Helvaci K, Geredeli C, Dane F, Balakan O, Ali Kaplan M, Gok Durnali A, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Ozkan M, Benekli M, Isikdogan A; Anatolian Society of Medical Oncology. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. J BUON. 2012 Jan–Mar;17(1):102–105.

• Babacan T, Sevinc A, Akarsu E, Balakan O. Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report. Chemotherapy. 2012 May 12;58(2):142–145.

• Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, Balakan O, Yasar N, Unal OU, Benekli M, Durnali A, Colak D, Sonmez OU. XELOX versus FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 2012 Apr 25;59(120).

• Balakan O, Süner A, Yiğiter R, Balakan T, Sirikçi A, Sevinç A. Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med. 2012;51(19):2819–2823. Epub 2012 Oct 1.

• Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Oncology. 2013;84(1):14–21.

• Demirci U, Tufan G, Aktas B, Balakan O, Alacacioglu A, Dane F, Engin H, Kaplan MA, Gunaydin Y, Ozdemir NY, Tugba Unek I, Karaca H, Akman T, Sonmez OU, Coskun U, Harputluoglu H, Sevinc A, Tonyali O, Buyukberber S, Benekli M. Bevacizumab plus irinotecan in recurrent or progressive malignant glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Cancer Res Clin Oncol. 2013 Feb 12.

• Inal A, Akman T, Yaman S, Demir Ozturk S, Geredeli C, Bilici M, Inanc M, Harputoglu H, Demirci U, Balakan O, Yesil Cinkir H, Alici S, Uysal Sonmez O, Goksel G, Gokoz Dogu G, Umit Unal O, Tamozlu T, Buyukberber S. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node-positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). J BUON. 2013 Jan–Mar;18(1):64–69.

• Balakan O, Babacan T, Altundag K. Vemurafenib-induced hypertension: is it real? J BUON. 2013 Apr–Jun;18(2):545.

• Babacan T, Sarici F, Gokhan A, Balakan O, Keskin O, Altundag K. Granulocyte colony-stimulating factor-induced tumor lysis-like syndrome: leucolysis. J BUON. 2013 Apr–Jun;18(2):549–550.

• Sarici F, Babacan T, Altundag K, Balakan O, Gullu I. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON. 2013 Jul–Sep;18(3):799.

• Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: a retrospective multicenter experience. Oncol Lett. 2013 Aug;6(2):605–611. Epub 2013 Jun 17.

• Inal A, Akman T, Yaman S, Ozturk SC, Geredeli C, Bilici M, Inanc M, Harputoglu H, Demirci U, Balakan O, Cınkır HY, Alıcı S, Colak D, Sonmez OU, Goksel G, Dogu GG, Engin H, Unal OU, Tamozlu T, Buyukberber S, Boruban CM, Isıkdogan A. Pathologic and clinical characteristics of elderly patients with breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). Int Surg. 2014 Jan–Feb;99(1):2–7.

• Berk V, Kaplan MA, Tonyali O, Buyukberber S, Balakan O, Ozkan M, Demirci U, Ozturk T, Bilici A, Tastekin D, Ozdemir N, Unal OU, Oflazoglu U, Turkmen E, Erdogan B, Uyeturk U, Oksuzoglu B, Cinkir HY, Yasar N, Gumus M. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev. 2013;14(12):7367–7369.

• Babacan T, Turkbeyler IH, Dag MS, Dilli I, Balakan O, Altundag K. Cetuximab-induced esophageal ulcer: the first report in literature. Libyan J Med. 2014 Feb 24;9:23723.

• Babacan T, Türkbeyler IH, Balakan O, Pehlivan Y, Suner A, Kısacık B. A case of vemurafenib-induced polyarthritis in a patient with melanoma: how to manage it? Int J Rheum Dis. 2014 May 12.

• Gogebakan B, Bayraktar R, Suner A, Balakan O, Ulasli M, Izmirli M, Oztuzcu S, Camci C. Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines? Tumour Biol. 2014 Aug;35(8):8033–8041.

• Balakan O, Kalender ME, Suner A, Cengiz B, Oztuzcu S, Bayraktar R, Borazan E, Babacan T, Camci C. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit. 2014 Aug 12;20:1419–1425.

• Alıcı H, Balakan O, Ercan S, Çakıcı M, Yavuz F, Davutoğlu V. Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer. Anadolu Kardiyol Derg. 2015 Jan;15(1):56–60.

• Unal OU, Oztop I, Kos T, Assoc, Turan N, Kucukoner M, Helvaci K, Berk V, Sevinc A, Yildiz R, Cinkir HY, Tonyali O, Demirci U, Aktas B, Balakan O, Yilmaz AU. Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO). Asian Pac J Cancer Prev. 2014;15(22):9687–9692.

• Kalender ME, Buyukhatipoglu H, Balakan O, Suner A, Dirier A, Sevinc A, Bulbul F, Tatli AM, Ulas T, Camci C. Depression, anxiety and quality of life through the use of complementary and alternative medicine among breast cancer patients in Turkey. J Cancer Res Ther. 2014 Oct–Dec;10(4):962–966.

• Buyukhatipoglu H, Babacan T, Kertmen N, Balakan O, Suner A, Ates O, Sarici F, Aslan A, Diker O, Tasdemir V, Ozisik Y, Altundag K. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer. J BUON. 2015 Jan–Feb;20(1):22–27.

• Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundag K. The effect of renin–angiotensin–system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON. 2015 Jan–Feb;20(1):50–56.

• Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015 Apr 27;101(4):418–423.

• Babacan T, Buyukhatipoglu H, Balakan O, Kertmen N, Suner A, Sarici F, Akin S, Ates O, Karakas Y, Aslan A, Diker O, Altundag K. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis. J BUON. 2015 Mar–Apr;20(2):479–486.

• Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B, Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Clinical significance of HER2 overexpression in gastric and gastroesophageal junction cancers. J Gastrointest Surg. 2015 Sep;19(9):1565–1571.

Other International Journal Publications

• Akkoyun M, Ardıç I, Balakan O, Deniz MS, Acar G. Case images: Isolated thrombus-like mass in a patient with multiple myeloma. Turk Kardiyol Dern Ars. 2014 Jun;42(4):413.

• Mehmet K, Sener C, Uyeturk U, Seker M, Tastekin D, Tonyali O, Balakan O, Yazici OK, Urakci Z, Isikdogan A, Ozdemir N, Inal A, Kaplan MA, Suner A, Dal S, Uncu D, Gumus M, Boruban MC, Oksuzoglu B, Ayyildiz O, Benekli M. Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. Contemp Oncol (Pozn). 2014;18(4):273–278.

• Suner A, Buyukhatipoglu H, Balakan O, Kalender ME, Ulas T, Sevinc A, Camci C. Importance of HER2 work-up and treatment even in patients with poor performance status: a case report. Case Rep Oncol Med. 2014;2014:731581.

• Ulasli M, Gurses S, Cengiz B, Oztuzcu S, Balakan O, Suner A, Gogebakan G, İgci M, Balik A, Arslan A, Camci C. Expression of PARP1 gene in breast cancer patients. UHOD. 2013;23:213–218.

• Karaca H, Geredeli C, Kaplan MA, Demirci U, Alici S, Artac M, Isikdogan A, Benekli M, Balakan O, Arpaci E, Budakoglu B, Uncu D, Guler T, Berk V, Özkan M. Efficacy and safety of erlotinib in previously treated advanced non-small cell lung cancer. UHOD. 2013;23:1–6.

• Kucukoner M, Balakan O, Kaplan MA, Inal A, Alabalik U, Urakci Z, Dal MS, Yildiz Y, Isikdogan A. Helicobacter pylori in primary gastric lymphoma and gastric cancer: a clinicopathologic and prognostic assessment. J Microbiol Infect Dis. 2013;3(2):61–66.

Presentations at International Scientific Meetings (Proceedings Publications)

• Acar G, Kaya H, Akcay A, Sökmen A, Balakan O, Köroglu S, Nacar AB, Suner A, Şahin M, Sökmen G, Sayarlioglu M, Tuncer C. Diastolic function abnormalities in patients with Behcet’s disease: a tissue Doppler study. 6th Congress of Update in Cardiology and Cardiovascular Surgery in conjunction with 59th International Congress of the European Society for Cardiovascular Surgery, İzmir, Turkey, 15–18 April 2010. Int J Cardiol. 2010;140(Suppl 1):S1–S93.

• Inal A, Isikdogan A, Kos T, Algin E, Gumus M, Dikilitas M, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Gok Durnali A, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Yildiz R, Kaplan MA, Ozkan M, Uncu D. Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: a retrospective analysis of multicenter study. ASCO 2011, Chicago.

• Turan N, Koca D, Dane F, Özdemir N, Oven BB, Ustaalioglu I, Oztop I, Ulas A, Berk V, Kucukoner M, Balakan O, Ozturk MA, Benekli M, Gumus M, Yilmaz U, Ozkan S, Buyukberber S. The impact of bevacizumab usage on patients who were curatively resected for liver-confined metastases from colorectal cancer. ASCO 2011, Chicago.

• Balakan O, Süner A, Öztuzcu S, Cengiz B, Kalender ME, Özkara E, Camci C. An analysis of the relationship between urotensin II and clinicopathological parameters of breast cancer. Gaziantep University School of Medicine, 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• Çiltaş A, Büyükberber S, Yıldız R, Arpacı E, Budakoğlu B, Küçüköner M, Şendur MA, Balakan O, Kefeli U, Berk V, Harputluoğlu H, Öksüzoğlu B, Uncu D, Kaya AO, Alkış N, Gümüş M, Benekli M, Coşkun U. Efficacy and toxicity evaluation of cisplatin + capecitabine chemotherapy in locally advanced and metastatic gastric cancer patients (Multicentric Study of the Anatolian Society of Medical Oncology). 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• Çiltaş A, Koca D, Yılmaz U, Büyükberber S, Eşbah O, İnalt A, Öztop İ, Binicier Ö, Köş T, İnanç M, Öksüzoğlu B, Isikdogan A, Uncu D, Özkan M, Yazici OK, Balakan O, Sevinç A, Coşkun U, Benekli M. Retrospective evaluation of tolerability and efficacy of neo-adjuvant chemoradiotherapy in locally advanced rectal cancer patients. 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• İnalt A, Akman T, Yaman S, Ozturk SD, Geredeli Ç, Bilici M, İnanc M, Harputoğlu H, Demirci U, Balakan O, Yesil Cınkır H, Alıcı S, Uysal Sonmez Ö, Göksel G, Gokoz Dogu G, Unal OU, Tamozlu T, Buyukberber S, Boruban CM, Isikdogan A. Endocrine therapy alone versus chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node-positive breast cancer: a retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• İnalt A, Akman T, Yaman S, Ozturk SC, Geredeli Ç, Bilici M, İnanc M, Harputoglu H, Demirci U, Balakan O, Yesil Cınkır H, Alıcı S, Colak D, Uysal Sonmez Ö, Goksel G, Gokoz Dogu G, Engin H, Unal OÜ, Tamozlu T, Buyukberber S, Boruban CM, Isıkdogan A. Pathological and clinical characteristics of elderly patients with breast cancer: multicenter study (Anatolian Society of Medical Oncology). 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• İnalt A, Akman T, Yaman S, Ozturk SC, Geredeli Ç, Bilici M, İnanc M, Harputoglu H, Demirci U, Balakan O, Yesil Cınkır H, Alıcı S, Uysal Sonmez Ö, Engin H, Unal OÜ, Tamozlu T, Isıkdogan A. Endocrine therapy alone versus chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node-negative breast cancer: a retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• Karaca H, Geredeli Ç, Kaplan MA, Demirci U, Alici S, Artaç M, Isikdogan A, Benekli M, Balakan O, Arpaci E, Budakoglu B, Uncu D, Guler T, Berk V, Ozkan M. The safety and efficacy of erlotinib in previously treated advanced non-small-cell lung cancer: multicenter experience. 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• Kefeli U, Benekli M, Sevinc A, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Yildiz R, Coskun U, Dane F, Harputluoglu H, Karaca H, Kaya AO, Demirci U, Gumus M, Buyukberber S. Efficacy of sorafenib in Turkish patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: retrospective multicenter experience. 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

• Kucukoner M, Isikdogan A, Sener C, Uyeturk U, Seker M, Tastekin D, Tonyali Ö, Balakan O, Yazici OK, Ozdemir N, Inal A, Kaplan MA, Suner A, Uncu D, Turkeli M, Demirci U, Urakci Z, Gumus M, Boruban MC, Oksuzoglu B, Benekli M. Primary gastric lymphoma: study of Anatolian Society of Medical Oncology. 1st NEMA Congress, 29 November–2 December 2012, Istanbul, Turkey.

National Peer-Reviewed Journal Publications

• Kıdır V, Aldemir M, Balakan O. Spontaneous retroperitoneal hemorrhages mimicking acute abdomen in Hemophilia-A patients. Çağdaş Cerrahi Dergisi. 2003;17(4):243–247.

• Tankrıkulu AÇ, Süner A, Balakan O, Aldemir M, Gürkan F. Diagnostic approach to abdominal tuberculosis cases. Çağdaş Cerrahi Dergisi. 2003;17(4):212–215.

• Aldemir M, Süner A, Kıdır V, Balakan O, Çelenk T. Spontaneous rupture of the spleen in a hemodialysis patient. European Journal of General Medicine. 2004;1(3):51–54.

• Aldemir M, Güloğlu C, Balakan O, Süner A, Kaya Z. Thyrotoxic periodic paralysis: a case report and review of the literature. European Journal of General Medicine. 2004;1(2):48–51.

• Soyoral Y, Süner A, Kıdır V, Arıtürk Z, Balakan O, Değertekin H. Effects of viral cirrhosis on cardiac ventricular function. European Journal of General Medicine. 2004;1(2):15–18.

• Kıdır V, Balakan O, Süner A, Şit D, Ayyıldız O. A case of multiple atrial thrombi in a splenectomized patient with thalassemia major. Türk Hematoloji Onkoloji Dergisi. 2005;15(2):100–103.

• Süner A, Balakan O, Kıdır V, Kara İH. Coexistence of thalassemia minor and lead intoxication in a patient presenting with hypochromic microcytic anemia. Uluslararası Hematoloji Onkoloji Dergisi. 2006;16(3):133–136.

• Balakan O, Kıdır V, Süner A, Yalçın K. Evaluation of inflammatory bowel disease cases at Dicle University Faculty of Medicine Hospital between 1995 and 2005. Düzce Üniversitesi Tıp Fakültesi Dergisi. 2007;3:26–30.

• Kalender ME, Demiryürek Ş, Öztuzcu S, Kızılyer A, Demiryürek AY, Balakan O, Camcı C. Association between ROCK1 gene Lys222Glu and Arg1262Gln polymorphisms and breast cancer: a Gaziantep Medical study. Gaziantep Tıp Dergisi. 2011;17(2):77–81.

• Suner A, Tutar E, Kalender ME, Kazancı Ü, Arslan SK, Balakan O, Karataş E, Kanlıkama M. The relationship between prognostic parameters and tumor-associated tissue eosinophilia in supraglottic laryngeal tumors. Gaziantep Tıp Dergisi. 2013;40(1):45–49.

• Balakan O, Sevinc A. What should we do for improved survival in metastatic malignant melanoma with brain metastasis? Türkiye Klinikleri J Med Oncol – Special Topics. 2014;7(2):75–82.

National Scientific Meetings and Conference Proceedings

• Ayyıldız O, Kıdır V, Söker M, Işıkdoğan A, Süner A, Kara İH, Balakan O, Çelik M, Müftüoğlu E. Long-term follow-up results of patients with acute and chronic idiopathic thrombocytopenia: a combined prospective and retrospective study. Turkish Hematology Society, 31st National Congress, 23–28 September 2004, Antalya.

• Süner A, Balakan O, Kıdır V, Kara İH. Coexistence of thalassemia minor and lead intoxication in a patient presenting with hypochromic microcytic anemia. 3rd National Family Medicine Days (International Participation), 25–28 May 2005, Kuşadası.

• Yalçın K, Yakut M, Seven G, Balakan O, Değertekin H. Clinical, serological, etiological, and prognostic characteristics of acute liver failure: a multicenter retrospective study. 5th National Hepatology Congress, 5–7 June 2005, Istanbul.

• Balakan O, Kıdır V, Yalçın K, Değertekin H. Cytokine levels in chronic Hepatitis Delta and B virus infections. 22nd National Gastroenterology Week, 30 August–4 September 2005, Malatya.

• Balakan O, Yalçın K, Süner A, Batun S. Lymphocyte CD ratios in chronic Hepatitis Delta and B virus infections. 22nd National Gastroenterology Week, 30 August–4 September 2005, Malatya.

• Balakan O, Kıdır V, Süner A, Yalçın K. Evaluation of inflammatory bowel disease cases. 22nd National Gastroenterology Week, 30 August–4 September 2005, Malatya.

• Sevinç A, Kalender ME, Camcı C, İğci M, Tutar E, Öztuzcu S, Göğebakan B, Balakan O, Cengiz B. Frequency of c-kit and PDGFRA gene mutations in gastrointestinal stromal tumors. 6th National Medical Oncology Congress, 24–28 September 2009, Antalya.

• Yıldız R, Büyükberber S, Yıldırım Özdemir N, Berk V, Kaplan MA, Üner A, Alkış N, Coşkun U, Uncu D, Balakan O, Camcı C, Yamaç D, Işıkdoğan A, Yetişyiğit T, Özkan M, Dane F, Altınbaş M, Zengin N, Benekli M. Evaluation of toxicity and response in metastatic colorectal cancer patients receiving bevacizumab-based combination chemotherapy: multicenter retrospective study (ATOD). 6th National Medical Oncology Congress, 24–28 September 2009, Antalya.

• Turan N, Dane F, Büyükberber S, Ustaalioğlu BÖ, Berk V, Özdemir N, Küçüköner M, Gümüş M, Balakan O, Özkan M, Coşkun U, Benekli M. Adjuvant chemotherapy applications after complete surgical resection in liver-metastatic colorectal cancer. 7th National Medical Oncology Congress, 22–26 September 2010, Antalya.

• Balakan O, Süner A, Sevinç A, Balık A, Camcı C. A case of lymphangioma mimicking metastatic liver tumor. 7th National Medical Oncology Congress, 22–26 September 2010, Antalya.

• Cengiz B, Çoban S, Camcı C, Öztuzcu S, Aksoy B, Balakan O, Göğebakan B, Kaplan DS, Başkonuş İ, Balık A. CDC25A gene -350C/T and -51C/G polymorphisms in pancreatic cancer. 7th National Medical Oncology Congress, 22–26 September 2010, Antalya.

• İnal A, Köş FT, Algın E, Yıldız R, Berk V, Ünek İT, Çolak D, Küçüköner M, Elkıran ET, Helvacı K, Geredeli Ç, Dane F, Balakan O, Kaplan MA, Gök Durnalı A, Harputluoğlu H, Göksel G, Özdemir N, Büyükberber S, Gümüş M, Özkan M, Işıkdoğan A. Prognostic factors affecting survival in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine alone vs gemcitabine + cisplatin (ATOD study). 8th National Medical Oncology Congress, Antalya 2011.

• İnal A, Işıkdoğan A, Köş FT, Algın E, Gümüş G, Dikilitaş M, Elkıran ET, Helvacı K, Geredeli Ç, Dane F, Balakan O, Gök Durnalı A, Harputluoğlu H, Göksel G, Özdemir N, Kaplan MA, Özkan M, Uncu D, Büyükberber S. Retrospective evaluation of efficacy and toxicity of gemcitabine vs gemcitabine + cisplatin combination in locally advanced and metastatic pancreatic cancer: ATOD study. 3rd National Gastrointestinal Oncology Congress, 7–10 April 2011, Antalya.

• İnal A, Öztürk SC, İnanç M, Geredeli Ç, Alıcı S, Harputluoğlu H, Çolak D, Sönmez ÖU, Balakan O, Doğu GG, Göksel G, Işıkdoğan A. Tumor characteristics in elderly breast cancer patients (ATOD study). 8th National Medical Oncology Congress, Antalya 2011.

• Karaca H, Geredeli Ç, Kaplan MA, Demirci U, Alıcı S, Börücü MC, Işıkdoğan A, Benekli M, Balakan O, Arpacı E, Budakoğlu B, Uncu D, Güler T, Özkan Ö. Evaluation of efficacy and adverse effects of erlotinib in non-small-cell lung cancer: ATOD study. 8th National Medical Oncology Congress, Antalya 2011.

• Karaca H, Özkan M, Ulaş A, Demirci U, Yıldırım Özdemir N, Berk V, Uysal Sönmez Ö, Küçüköner M, Alkış N, Uncu D, Gökoz Doğu G, Balakan O, Çolak D, Öven Ustaalioğlu B, Alıcı S, Büyükberber S. Neuroendocrine tumor database: multicenter retrospective evaluation (ATOD study). 8th National Medical Oncology Congress, Antalya 2011.

• Küçüköner M, Işıkdoğan A, Üyetürk Ü, Öksüzoğlu B, Şeker M, Gümüş M, Tonyali Ö, Benekli M, Balakan O, Camcı C, Türkeli M, Demirci U, Büyükberber S. Clinical-pathological and prognostic evaluation of primary gastric lymphoma patients: multicenter ATOD study. 8th National Medical Oncology Congress, Antalya 2011.

• Balakan O, İnanç M, Sevinç A, Özkan M, Alıcı S, Camcı C. Retrospective evaluation of liposomal doxorubicin (modified CALYPSO) in recurrent epithelial ovarian cancer (ATOD study). 8th National Medical Oncology Congress, Antalya 2011.

• Camcı C, Sevinç A, Öztuzcu S, Ulaşlı M, Kalender ME, Süner A, Balakan O, Cengiz B, Bayraktar R, Arslan A. PARP-1 gene expression in breast cancer patients. 8th National Medical Oncology Congress, Antalya 2011.

• Camcı C, Sevinç A, Öztuzcu S, Ulaşlı M, Kalender ME, Süner A, Balakan O, Cengiz B, Geyik F, Arslan A. An alternative perspective in breast cancer: RHO/ROCK pathway. 8th National Medical Oncology Congress, Antalya 2011.

• Berk V, Özdemir N, Özkan M, Aksoy S, Turan N, İnal A, Balakan O, Yaşar N, Ünal OÜ, Benekli M, Durnalı A, Çolak D. Evaluation of efficacy and adverse effects of oxaliplatin-containing regimens as second-line therapy in metastatic pancreatic cancer: ATOD study. 8th National Medical Oncology Congress, Antalya 2011.

• Turan N, Koca D, Ustaalioğlu BÖ, Dane F, Özdemir N, Ulaş A, Öztop İ, Gümüş M, Öztürk MA, Berk V, Küçüköner M, Üner A, Balakan O, Helvacı K, Özkan S, Yılmaz U, Benekli M, Büyükberber S. Contribution of bevacizumab combinations in adjuvant chemotherapy after complete surgical resection in liver-metastatic colorectal cancer: ATOD study. 8th National Medical Oncology Congress, Antalya 2011.

• Turan N, Dane F, Koca D, Berk V, Ustaalioğlu BÖ, Üner A, Öztop İ, Helvacı K, Gümüş M, Özdemir N, Balakan O, Küçüköner M, Yılmaz U, Benekli M, Büyükberber S. Prognostic factors affecting survival after complete resection in lung-metastatic colorectal cancer: ATOD study. 8th National Medical Oncology Congress, Antalya 2011.

• Balakan O, Kalender ME, Süner A, Balakan T, Sevinç A. Gemcitabine-induced gynecomastia in a male patient with pancreatic cancer. 8th National Medical Oncology Congress, Antalya 2011.

• Turan N, Koca D, Dane F, Özdemir N, Ustaalioğlu BÖ, Öztop İ, Ulaş A, Berk V, Balakan O, Küçüköner M, Öztürk MA, Benekli M, Gümüş M, Yılmaz U, Özkan S, Büyükberber S. Adjuvant chemotherapy applications after complete surgical resection in liver-metastatic colorectal cancer. 3rd National Gastrointestinal Oncology Congress, 7–10 April 2011, Antalya.

• Çiltaş A, Koca D, Yılmaz U, Büyükberber S, İnal A, Öztop İ, Binicier Ç, Köş T, Işıkdoğan A, Özdemir N, Eşbah O, Alıcı S, Balakan O, Coşkun U, Benekli M. Retrospective evaluation of efficacy and tolerability of neoadjuvant chemoradiotherapy in locally advanced rectal cancer: ATOD study. 3rd National Gastrointestinal Oncology Congress, 7–10 April 2011, Antalya.

• Yılmaz M, Kalender E, Balakan O, Süner A, Çelen Z, Camcı C. Role of PET-CT in staging of esophageal cancer. 3rd National Gastrointestinal Oncology Congress, 7–10 April 2011, Antalya.

• Sevinç A, Şeker M, Balakan O, Yıldız R, Kaplan MA, Cihan Ş, Karca H, Gökdurnalı A, Büyükberber S. Evaluation of patients with gastrointestinal stromal tumors receiving sunitinib: multicenter study. 3rd National Gastrointestinal Oncology Congress, 7–10 April 2011, Antalya.

• Cengiz B, Çoban S, Camcı C, Öztuzcu S, Aksoy B, Balakan O, Göğebakan B, Arslan A, Başkonuş İ, Balık A. Relationship between CDC25A gene expression and promoter polymorphisms in pancreatic cancer. 3rd National Gastrointestinal Oncology Congress, 7–10 April 2011, Antalya.

• Çiltaş A, Büyükberber S, Yıldız R, Arpacı E, Budakoğlu B, Küçüköner M, Şendur MA, Balakan O, Kefeli U, Berk V, Harputluoğlu H, Öksüzoğlu B, Uncu D, Alkış N, Gümüş M, Benekli M, Coşkun U. Evaluation of efficacy and toxicity of cisplatin + capecitabine chemotherapy in locally advanced and metastatic gastric cancer: multicenter ATOD study. 4th National Gastrointestinal Oncology Congress, 11–15 April 2012, Antalya.

• Berk V, Özdemir N, Özkan M, Aksoy S, Turan N, İnal A, Balakan O, Yaşar N, Ünal OÜ, Durnalı A, Çolak D, Uysal Sönmez Ö, Benekli M. Comparison of XELOX vs FOLFOX4 as second-line therapy in advanced pancreatic cancer: ATOD study. 4th National Gastrointestinal Oncology Congress, 11–15 April 2012, Antalya.

• Balakan O, Özkara E, Öztuzcu S, Camcı C, Arslan A, Demiryürek AT. Investigation of association between RhoC gene polymorphism and colorectal cancer. 4th National Gastrointestinal Oncology Congress, 11–15 April 2012, Antalya.

• Öztuzcu S, Özkara E, Süner A, Ulaşlı M, Balakan O, Demiryürek AT, Camcı C. Association between Endothelin 3 (EDN3) gene rs12322 polymorphism and colorectal cancer. 4th National Gastrointestinal Oncology Congress, 11–15 April 2012, Antalya.

• Balakan O, Özkara E, Öztuzcu S, Camcı C, Arslan A, Demiryürek AT. Association between RhoB gene polymorphism and colorectal cancer. 4th National Gastrointestinal Oncology Congress, 11–15 April 2012, Antalya.

• Balakan O, Özkara E, Öztuzcu S, Camcı C, Arslan A, Demiryürek AT. Association between RhoA gene polymorphism and colorectal cancer. 4th National Gastrointestinal Oncology Congress, 11–15 April 2012, Antalya.

Internal Medicine Specialty Thesis Summary

• Comparison of Plasma Cytokine and CD Levels in Patients with Chronic Delta Hepatitis, Chronic Hepatitis B, and Resolved Hepatitis B
  • Thesis Advisor: Assoc. Prof. Kendal Yalçın
  • This study included 152 patients followed at Dicle University Hospital Gastroenterology Outpatient Clinic with chronic Hepatitis B or Delta Hepatitis diagnoses, and 42 healthy individuals with resolved Hepatitis B, between December 2003 and May 2005. Diagnosis was established through patient history, physical examination, biochemical parameters, serum HBV markers, HBV-DNA, anti-HDV antibodies, HDV RNA, and percutaneous liver biopsy for those who consented.
  • The study investigated CD ratios (CD3, CD4, CD8, CD56, CD4/CD8) and plasma inflammatory cytokines (IL-1β, IL-2 receptor, IL-6, IL-8, IL-10, TNF-α), which are thought to play a role in the chronicity of Hepatitis B infection.
  • Results showed that mean CD3, CD4, CD8, and CD56 levels in all groups (chronic Hepatitis B, chronic Delta Hepatitis, and resolved Hepatitis B) were within normal adult ranges. Intergroup comparison revealed no statistically significant differences except for CD4 levels between chronic Hepatitis B and Delta Hepatitis patients. Mean CD4/CD8 ratios were within normal limits in all groups. IL-1β levels were extremely low and undetectable in all groups. In patients with chronic hepatitis, IL-2 receptor, IL-8, and TNF-α levels were significantly higher than in the resolved Hepatitis B group (P<0.05). TNF-α and IL-8 levels were elevated in the HDV group compared to the HBV group (P<0.05). No significant difference was found in cytokine levels between cirrhotic and non-cirrhotic patients (P>0.05). Positive correlations were found between TNF-α and IL-2 receptor with ALT levels and hepatic activity index (P<0.05).
  • These findings suggest that cytokines may be used as markers to assess the immune response and disease activity in hepatitis patients.

Medical Oncology Subspecialty Thesis Summary

• Investigation of the Relationship Between Urotensin 2 and Clinical and Pathological Parameters in Breast Cancer
  • Thesis Advisor: Prof. Dr. Celaletdin Camcı
  • Some vasoactive peptides are produced and secreted by tumor cells and act as paracrine growth stimulators. This study aimed to investigate the potential relationship between the mRNA expression of the vasoactive peptide urotensin 2 and its receptor in breast cancer.
  • A total of 59 female patients with a median age of 48 were included. Fresh tumor tissue and healthy breast tissue samples were analyzed for urotensin 2 and urotensin 2 receptor mRNA expression, and correlations with clinical and pathological parameters were assessed.
  • Urotensin 2 and its receptor mRNA expression was detected in 55 of 59 tumor tissues and 55 of 59 normal breast tissues. A strong positive correlation was observed between urotensin 2 and its receptor (r=0.632, p=0.001). Age showed a weak negative correlation with urotensin 2 receptor expression (r=-0.281, p=0.038). Urotensin 2 and receptor levels were higher in premenopausal patients compared to postmenopausal patients (p<0.05). Urotensin 2 receptor expression was higher in patients without extranodal invasion compared to those with extranodal invasion (p=0.001). Urotensin 2 expression was borderline significantly higher in patients without lymphatic invasion (p=0.048).
  • This study is the first in the literature to demonstrate urotensin 2 and its receptor mRNA expression in both normal breast and breast cancer tissues. Urotensin 2 appears to be associated with menopausal status, extranodal invasion, and lymphatic invasion.